Endocrine Abstracts

There are three distinct types of gastric Neuroendocrine tumours using the ENETS classification system. Type 1 gastric NETs are most common, accounting for 55–70% of all gastric NETs. Epidemiology studies have suggested an increasing incidence of gastric NETs. Generally type 1 gastric NETs are multifocal in nature and arise in a background of chronic atrophic gastritis. Type 1 Gastric NETs arise from histamine secreting ECL cells, hypergastrinaemia due to excess gastrin r...

Introduction: Pulmonary NENs account for around 2% of all pulmonary malignancy. They are classified histologically into 4 types typical and atypical carcinoids which are generally well differentiated and large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC) which are poorly differentiated. Within the literature there are several reports regarding overall survival on small mainly surgical cohorts, but data for the UK population are lacking. Only a few...

Background: Gastric and duodenal neuroendocrine tumours are increasing in incidence. ENETS guidelines suggest endoscopic resection of type 1 gastric NENs over 10 mm and consider endoscopic resection for duodenal NENs. However, the endoscopic techniques are not clearly mandated. There, is evidence to suggest endoscopic mucosal dissection has higher incidence of R0 resections compared with polypectomy or EMR alone. We have reviewed our data of endoscopic resection of gastro-duod...

Introduction: Up to half of patients with carcinoid syndrome develop carcinoid heart disease; this is thought to be mediated by serotonin from disordered tryptophan metabolism. Valve degeneration can lead to right heart failure which drives morbidity and mortality in this patient population. Surgical replacement of affected valves is an effective therapy. Peptide receptor radiotargeted therapy (PRRT) has demonstrated better progression-free survival compared to high dose sando...

Introduction: Neuroendocrine tumours (NETs) may change grade and clinical behaviour substantially over time, requiring shifts in management strategy.Case Presentation: A 53-year-old lady presented with abdominal bloating and diarrhoea. Diagnostic MRCP and CT-CAP confirmed metastatic cancer, with bilobar liver metastases and a sclerotic lesion in the right ilium. Her disease was 68Ga-DOTATATE-avid. Rectal biopsy confirmed...

Background: Symptom management is a cornerstone of clinical care, particularly for patients with cancer. However, often patient’s symptoms go undetected by health care providers between clinic visits. Mobile health applications are increasingly used in oncological care to support cancer patients.Aims: To develop a patient focussed mobile application to enable patients to track symptoms, record quality of life, communicate with their clinical teams a...

Introduction: Gastric NENs are increasingly being diagnosed at endoscopy. The majority of these are type 1 gastric NEN. However, around 10–20% can be type 3 or type 4 Gastric NENs.Methods: A retrospective review performed of 54 patients with gastric NENs referred to a tertiary centre during 2014 to 2019.Results: Of the 54 cases referred, 45 were type 1 gastric NENs and the 9 were type 3 Gastric NENs. Of the 45 type 1 gastric N...

Digital technology has an important role in the monitoring and management of long term conditions. The purpose of this study was to evaluate the feasibility of using PROMS to monitor symptoms, via a disease specific mobile application. Secondary endpoints included QoL and patient engagement. In addition, we reviewed the total number of symptoms reports and time required for patients to complete and submit these.Methods: Unmet patient nee...

Introduction: The incidence and prevalence of GEP-NENs is rising worldwide. NENs represent the group off well differentiated neuroendocrine tumours (NET) and poorly differentiated neuroendocrine carcinoma (NEC). NETs can be divided into grade 1 (G1), grade 2 (G2) and grade 3 (G3) based on histological parameters. There exist several studies regarding survival data but these are mainly based on national databases.Aim: To describe the real world overall su...

Neuroendocrine tumours (NETs) occur in multiple tissues and vary widely in clinical behaviour. Up to 70% of diagnosed patients have elevated circulating levels of chromogranin A, the only serum marker commonly used in clinical practice. However, its low sensitivity and the identification of confounding factors that compromise specificity have raised the need for additional or alternative markers for disease detection and management. Here we aimed to discover candidate NET mark...